Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24179988 | 0.90 | MEN1 (0.43) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL21031905 | 0.84 | KDM4E (0.44) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL21031895 | 0.84 | NAMPT (0.44) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL21031899 | 0.83 | KDM4E (0.42) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL24179990 | 0.76 | NAMPT (0.43) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL18082655 | 0.75 | KMT2A (0.42) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL24179991 | 0.74 | KDM4E (0.41) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL16119336 | 0.74 | KDM4E (0.47) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL31568301 | 0.71 | KDM4E (0.42) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL31643389 | 0.69 | MEN1 (0.59) | MEN1KMT2ATDP1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800765-B2 | Indole derivative used as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| US-20190248770-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
| EP-3489233-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248770-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | NR3C2, CRHR2, TPH2 | MEN1 2875/4885KMT2A 2348/4885KDM4E 4467/4885 |
| US-10800765-B2 | Indole derivative used as CRTH2 inhibitor | NR3C2, CRHR2, TPH2 | MEN1 2875/4885KMT2A 2348/4885KDM4E 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.